{"product_id":"leukemias-isbn-9781405182355","title":"Leukemias","description":"Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.  \u003cp\u003eTopics include:\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003eTargeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)\u003c\/li\u003e \u003cli\u003eRas inhibitors\u003c\/li\u003e \u003cli\u003eEpigenetic therapy (hypomethylaters and histone deacetylase inhibitors)\u003c\/li\u003e \u003cli\u003eLenalidomide analogs\u003c\/li\u003e \u003cli\u003eNew chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine\u003c\/li\u003e \u003cli\u003eCombinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)\u003c\/li\u003e \u003cli\u003eNew monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)\u003c\/li\u003e \u003cli\u003eThrombopoietic agents\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003eLeukemias: Principles and Practice of Therapy\u003c\/i\u003e\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003eIncludes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease\u003c\/li\u003e \u003cli\u003eIncorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area\u003c\/li\u003e \u003c\/ul\u003e  Contributors.  \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: Background and Diagnostic.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Stem Cell Biology in Normal and Malignant Hematopoiesis (\u003ci\u003eAmer Zeidan and Meir Wetzler\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e2. Epidemiology and Etiology of Leukemias (\u003ci\u003eAndrew Fletcher, Annika Whittle and David Bowen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e3. Traditional Diagnostic Approaches (\u003ci\u003eHartmut Koeppen, Carlos E. Bueso-Ramos and Sergej N. Konoplev\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e4. Diagnosis of Leukemias - New Diagnostic Modalities and Implications for Classification (\u003ci\u003eMaher Albitar\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e5. Non-cytogenetic Markers and Their Impact on Prognosis (\u003ci\u003eEric Schafer and Donald Small\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: Myelodysplastic syndromes (MDS).\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6. Myelodysplastic Syndromes: Pathophysiology (\u003ci\u003eSteven D. Gore and Erica Warlick\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e7. Myelodysplastic Syndromes - The Role of Cytogenetic and Molecular Abnormalities for Classification and Risk Assignment (\u003ci\u003eUlrich Germing\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e8. Myelodysplastic Syndromes (\u003ci\u003eWilliam Stevenson and Guillermo Garcia-Manero\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: Acute Myeloid Leukemia (AML).\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9. Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia (\u003ci\u003eWolfgang Kern, Torsten Haferlach, Susanne Schnittger, Claudia Haferlach, and Ulrike Bacher\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e10. Induction Therapy of Acute Myeloid Leukemia (\u003ci\u003eMartha Wadleigh and Daniel J. DeAngelo\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e11. Salvage Therapy for Acute Myeloid Leukemia: Current Strategies and Emerging Therapies (\u003ci\u003eKeith W. Pratz and Judith E. Karp\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e12. Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (\u003ci\u003eGheath Alatrash and\u003c\/i\u003e \u003ci\u003eMarcos de Lima\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4: Acute Promyelocytic Leukemia (APL).\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13. The Pathophysiology of Acute Promyelocytic Leukemia (\u003ci\u003eFrancesco Lo-Coco and Syed Khizer Hasan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e14. Acute Promyelocytic Leukemia (APL): Manifestations and Therapy (\u003ci\u003eSylvain Thépot, Lionel Ades, Pierre Fenaux\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5: Acute Lymphoblastic Leukemia (ALL).\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15. Acute Lymphoblastic Leukemia: Presentation, Diagnosis and Classification (\u003ci\u003eSandeep Gurbuxani and John Anastasi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e16. Induction Therapy in Adult Acute Lymphoblastic Leukemia (\u003ci\u003eXavier Thomas\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e17. Salvage Therapy of Adult Acute Lymphoblastic Leukemia (\u003ci\u003eNicola Gökbuget and Dieter Hoelzer\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e18. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Current Treatment Status and Perspectives (\u003ci\u003eOlga Sala-Torra and Jerald P. Radich\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e19. Acute Lymphoblastic Leukemia in Adolescents and Young Adults (\u003ci\u003eMichael E. Rytting\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e20. The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Lymphoblastic Leukemia (\u003ci\u003ePartow Kebriaei\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6: Chronic Myeloid Leukemia (CML).\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21. Pathophysiology of Chronic Myeloid Leukemia (\u003ci\u003eAgnes S. M. Yong and Junia V. Melo\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e22. Therapy of Newly Diagnosed and Chronic Phase Chronic Myelogenous Leukemia (\u003ci\u003eAndreas Hochhaus\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e23. Therapy of Advanced Stage and Resistant Chronic Myeloid Leukemia (\u003ci\u003eDevendra K. Hiwase and Timothy P. Hughes\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7: Chronic Lymphocytic Leukemia.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24. Chronic Lymphocytic Leukemia:  Pathophysiology, Diagnosis and Manifestations, and Prognostic Markers (\u003ci\u003eThorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e25. Therapy of Chronic Lymphocytic Leukemia – Frontline and Salvage (\u003ci\u003eValentin Goede, Barbara Eichhorst, and Michael Hallek\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e26. The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia (\u003ci\u003eSimon Hallam and John G. Gribben\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e27. Special Situations: Management of Elderly Patients and CLL Transformation (\u003ci\u003eWei-Gang Tong and Alessandra Ferrajoli\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8: Other Leukemic Disorders.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e28. Hairy Cell Leukemia (\u003ci\u003eFarhad Ravandi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e29. Therapeutic Approaches to the Mature T-cell Lymphoproliferative Leukaemias (\u003ci\u003eNnenna\u003c\/i\u003e \u003ci\u003eOsuji and Claire Dearden\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e30. Philadelphia Chromosome Negative Myeloproliferative Neoplasms (\u003ci\u003eRuben A. Mesa and Srdan Verstovsek\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9: General Treatment Principles and Clinical Developments.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31. Management of Emergencies in Leukemias (\u003ci\u003eOlga Frankfurt\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e32. Management of Infectious Complications in Patients with Leukemia (\u003ci\u003eMarcio Nucci, Nair Bijay and Elias Anaissie\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e33. Transfusion Support and Hematopoietic Growth Factors (\u003ci\u003ePaolo Rebulla\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e34. New Designs for Clinical Trials: AML as an Example (\u003ci\u003eElihu Estey\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eThe color plate section.\u003c\/p\u003e \"This high quality book will be an excellent reference for both fellows and attending physicians who care for patients with leukemic disorders in either a community or academic setting . . . This book is a welcome resource for those entering the field as well as for long-time practitioners who want to stay up to date.\" (Doody's, 12 August 2011)  \u003cp\u003e\u003cstrong\u003eDr. Stefan Faderl\u003c\/strong\u003e specializes in acute and chronic leukemias. His main areas of interest include acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and its variants, as well as chronic myeloid leukemias (CML). \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDr. Hagop M. Kantarjian\u003c\/strong\u003e is Professor of Medicine and Chairman of the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas. He specializes in leukemia and is interested in creating new treatment approaches for these diseases. He has authored and contributed to over 560 medical publications, articles, and abstracts.   Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.  \u003c\/p\u003e\u003cp\u003eTopics include:\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003eTargeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)\u003c\/li\u003e \u003cli\u003eRas inhibitors\u003c\/li\u003e \u003cli\u003eEpigenetic therapy (hypomethylaters and histone deacetylase inhibitors)\u003c\/li\u003e \u003cli\u003eLenalidomide analogs\u003c\/li\u003e \u003cli\u003eNew chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine\u003c\/li\u003e \u003cli\u003eCombinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)\u003c\/li\u003e \u003cli\u003eNew monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)\u003c\/li\u003e \u003cli\u003eThrombopoietic agents\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003eLeukemias: Principles and Practice of Therapy\u003c\/i\u003e\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003eIncludes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease\u003c\/li\u003e \u003cli\u003eIncorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989525577957,"sku":"NP9781405182355","price":215.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405182355.jpg?v=1761784460","url":"https:\/\/k12savings.com\/products\/leukemias-isbn-9781405182355","provider":"K12savings","version":"1.0","type":"link"}